Pharma BD Deal Intelligence
Non-dilutive Greater China license; global rights retained
Full analysis, sources & comparables →Aligos Therapeutics granted Xiamen Amoytop Biotech an exclusive license to develop and commercialize pevifoscorvir sodium, its clinical-stage HBV capsid assembly modulator, in Greater China for chronic hepatitis B. Aligos received a $25M upfront payment and is eligible for up to $420M in clinical, regulatory and sales milestones plus tiered high single-digit royalties on net sales in the licensed territory. Aligos retains all rights in the US, Europe, South Korea, Japan and other markets. Pevifoscorvir sodium holds Breakthrough Therapy Designation from China's NMPA Center for Drug Evaluation.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Xiamen Amoytop Biotech Co., Ltd. / Aligos Therapeutics, Inc. (this deal) | 2026 | $445M | 58 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2026 deals · Infectious Disease deals